Zobrazeno 1 - 10
of 71
pro vyhledávání: '"Douglas B. Muchmore"'
Autor:
Jasmin R. Kastner, Timothy S. Bailey, Poul Strange, Leon Shi, Keith A. Oberg, Paul J. Strasma, Jeffrey I. Joseph, Douglas B. Muchmore
Publikováno v:
Diabetes Technology & Therapeutics. 25:143-147
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e12b68126b8957709f7994d29c7d100e
https://doi.org/10.1089/dia.2022.0323
https://doi.org/10.1089/dia.2022.0323
Autor:
Ruth S. Weinstock, Bruce W. Bode, Satish K. Garg, David C. Klonoff, Caroline El Sanadi, W. Blair Geho, Douglas B. Muchmore, Marc S. Penn
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1762-1769
To investigate whether an increased bolus: basal insulin ratio (BBR) with liver-targeted bolus insulin (BoI) would increase BoI use and decrease hypoglycaemic events (HEv).We enrolled 52 persons (HbA1c 6.9% ± 0.12%, mean ± SEM) with type 1 diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f36d5c9020c078a560993d4d418d08ab
https://doi.org/10.1111/dom.14761
https://doi.org/10.1111/dom.14761
Autor:
Jasmin R. Kastner, Nisha Venkatesh, Katie Brown, Douglas B. Muchmore, Elif Ekinci, Spiros Fourlanos, Jeffrey I Joseph, Miami Shafeeq, Leon Shi, Poul Strange, Paul J. Strasma, David N. O'Neal
Publikováno v:
Diabetes, Obesity and Metabolism. 24:1143-1149
To assess the feasibility of a prototype insulin infusion set (IIS) for extended wear in adults with type 1 diabetes.The prototype Capillary Biomedical investigational extended-wear IIS (CBX IIS) incorporates a soft, flexible, reinforced kink-resista
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e473b3fe19db184e01b4690336636d0b
https://doi.org/10.1111/dom.14685
https://doi.org/10.1111/dom.14685
Autor:
Jasmin Renée, Kastner, Timothy S, Bailey, Poul, Strange, Leon, Shi, Keith A, Oberg, Paul, Strasma, Jeffrey I, Joseph, Douglas B, Muchmore
Publikováno v:
Diabetes technologytherapeutics.
Insulin exposure varies over 3 days of insulin infusion set (IIS) wear making day-to-day insulin dosing challenging for people with diabetes (PWD). Here we report pharmacodynamic (PD) and pharmacokinetic (PK) data extending these observations to 7 da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2c01eff7b256c2c7fe0fc15749b2f76d
https://pubmed.ncbi.nlm.nih.gov/36342853
https://pubmed.ncbi.nlm.nih.gov/36342853
Autor:
TIMOTHY S. BAILEY, JASMIN R. KASTNER, POUL STRANGE, LEI SHI, KEITH A. OBERG, JEFFREY I. JOSEPH, PAUL J. STRASMA, DOUGLAS B. MUCHMORE
Publikováno v:
Diabetes. 71
Insulin exposure and action are known to differ on each of 3 days of infusion set wear during CSII. We extend these observations to 1 week in a pilot phase study comparing conventional Teflon angled infusion sets to a prototype extended wear set usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc95d9d7e7f795623eb90281b349bf18
https://doi.org/10.2337/db22-781-p
https://doi.org/10.2337/db22-781-p
Autor:
null Jasmin R. Kastner, null Nisha Venkatesh, null Katie Brown, null Douglas B. Muchmore, null Elif Ekinci, null Spiros Fourlanos, null Jeffrey I Joseph, null Miami Shafeeq, null Leon Shi, null Poul Strange, null Paul J. Strasma, null David N. O’Neal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2623334936b66c066894d48155d69614
https://doi.org/10.1111/dom.14685/v3/response1
https://doi.org/10.1111/dom.14685/v3/response1
Publikováno v:
Vascular Health and Risk Management, Vol Volume 3, Pp 947-958 (2008)
Bernard L Silverman1, Christopher J Barnes2, Barbara N Campaigne3, Douglas B Muchmore31Alkermes, Inc, Cambridge, MA, USA; 2i3 Statprobe, Ann Arbor, MI; 3Eli Lilly and Company, Indianapolis, IN, USAAbstract: Diabetes mellitus is a significant worldwid
Externí odkaz:
https://doaj.org/article/144827c6b01645b1806af3d4867fef4d
Autor:
Richard J MacIsaac, Jasmin R. Kastner, David N O'Neal, Douglas B. Muchmore, Elif I Ekinci, Katrin Brown, Spiros Fourlanos, Nisha Venkatesh
Publikováno v:
Diabetes. 70
Background: Reliable insulin delivery is critical in the management of type 1 diabetes. Limitations of insulin pump therapy (IPT) are the maximum cannula life of three days, and a reported failure rate of 15-25% prior to this, which may impact glycem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eebe2663bfdf6cffed083dceb9711226
https://doi.org/10.2337/db21-701-p
https://doi.org/10.2337/db21-701-p
Publikováno v:
Journal of Diabetes Science and Technology. 13:3-7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4707dc9e9d122889fa260f35b7f0a492
https://doi.org/10.1177/1932296818817011
https://doi.org/10.1177/1932296818817011
Autor:
Marc S. Penn, Bruce W. Bode, Walter Geho, Kamalpreet K. Singh, Douglas B. Muchmore, Ruth S. Weinstock, Satish K. Garg, Caroline E. El Sanadi, David C. Klonoff
Publikováno v:
Diabetes. 69
Background: Subcutaneous (SC) insulin is non-physiologic, since normally insulin is secreted into the portal vein going directly to the liver. The OPTI-1 study was designed to determine whether delivery of Hepatic Directed Vesicles (HDV) admixed with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e144edabd90914326f6eb28a594125e7
https://doi.org/10.2337/db20-111-lb
https://doi.org/10.2337/db20-111-lb